Preliminary Q3 2025 unaudited net revenue of more than $100 million, including at least $85 million for DefenCath, and preliminary pro forma Q3 2025 unaudited Company net revenue of more than $125 million. DefenCath revenue growth has been driven by stronger than projected utilization by the Company’s LDO customer as well as continued utilization growth with other customers. Cash, cash equivalents and short-term investments as of September 30, 2025 accounted for approximately $56 million, and the Company is guiding to a projected year end cash and cash equivalent balance of approximately $100 million.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix files to sell 6.32M shares of common stock for holders
- Largest borrow rate increases among liquid names
- CorMedix completes enrollment in Phase III ReSPECT trial for REZZAYO
- Cormedix’s Strategic Growth: Melinta Acquisition and Rezzayo’s Market Expansion Justify Buy Rating
- Cormedix’s Positive Outlook: Buy Rating Backed by Strong Sales Guidance and Strategic Initiatives